(1) Synopsys' third quarter of fiscal year 2022 and fiscal year 2022 will end on July 30, 2022 and October 29, 2022, respectively. For presentation purposes, we refer to the closest calendar month end. |
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements regarding Synopsys' short-term and long-term financial targets, expectations and objectives; strategies related to our products and technology; business and market outlook, opportunities and strategies; customer demand and market expansion; our planned product releases and capabilities; industry growth rates; software trends; planned acquisitions and stock repurchases; our expected tax rate; the expected impact of U.S. and foreign government actions and regulatory changes on our financial results; and the continued impact of the COVID-19 pandemic. These statements involve risks, uncertainties and other factors that could cause our actual results, time frames or achievements to differ materially from those expressed or implied in our forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks from the continued impact of the COVID-19 pandemic on the global economy and on our business, operations and financial condition; macroeconomic conditions and uncertainty in the global economy; uncertainty in the growth of the semiconductor and electronics industries; the highly competitive industry we operate in; consolidation among our customers and our dependence on a relatively small number of large customers; risks and compliance obligations relating to the global nature of our operations as well as actions by the U.S. or foreign governments, such as the imposition of additional tariffs or export restrictions; and more. Additional information on potential risks, uncertainties and other factors that could affect Synopsys' results is included in filings we make with the Securities and Exchange Commission from time to time, including in the sections entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended October 31, 2021 and in our latest Quarterly Report on Form 10-Q. The information provided herein is as of May 18, 2022. Synopsys undertakes no duty, and does not intend, to update any forward-looking statement, whether as a result of new information, future events or otherwise, unless required by law.
SYNOPSYS, INC. | |||||||
Unaudited Condensed Consolidated Statements of Income (1) | |||||||
(in thousands, except per share amounts) | |||||||
| |||||||
| Three Months Ended |
| Six Months Ended | ||||
| April 30, |
| April 30, | ||||
| 2022 |
| 2021 |
| 2022 |
| 2021 |
Revenue: |
|
|
|
|
|
|
|
Time-based products | $ 723,821 |
| $ 648,794 |
| $ 1,431,304 |
| $ 1,280,084 |
Upfront products | 336,625 |
| 209,116 |
| 704,899 |
| 383,497 |
Maintenance and service | 218,783 |
| 166,413 |
| 413,281 |
| 331,063 |
Total revenue | 1,279,229 |
| 1,024,323 |
| 2,549,484 |
| 1,994,644 |
Cost of revenue: |
|
|
|
|
|
|
|
Products | 150,690 |
| 134,738 |
| 316,089 |
| 262,085 |
Maintenance and service | 87,666 |
| 67,840 |
| 165,891 |
| 136,606 |
Amortization of intangible assets | 14,455 |
| 11,408 |
| 27,815 |
| 23,294 |
Total cost of revenue | 252,811 |
| 213,986 |
| 509,795 |
| 421,985 |
Gross margin | 1,026,418 |
| 810,337 |
| 2,039,689 |
| 1,572,659 |
Operating expenses: |
|
|
|
|
|
|
|
Research and development | 389,964 |
| 362,345 |
| 773,935 |
| 719,813 |
Sales and marketing | 191,573 |
| 172,754 |
| 372,083 |
| 343,382 |
General and administrative | 73,957 |
| 72,694 |
| 154,965 |
| 150,182 |
Amortization of intangible assets | 6,912 |
| 8,313 |
| 15,912 |
| 16,703 |
Restructuring charges | 311 |
| - |
| 12,057 |
| - |
Total operating expenses | 662,717 |
| 616,106 |
| 1,328,952 |
| 1,230,080 |
Operating income | 363,701 |
| 194,231 |
| 710,737 |
| 342,579 |
Other income (expense), net | (23,913) |
| 21,764 |
| (43,706) |
| 50,520 |
Income before income taxes | 339,788 |
| 215,995 |
| 667,031 |
| 393,099 |
Provision for income taxes | 45,896 |
| 21,193 |
| 59,798 |
| 36,269 |
Net income | 293,892 |
| 194,802 |
| 607,233 |
| 356,830 |
Net income (loss) attributed to non-controlling interest and
| (889) |
| (276) |
| (1,235) |
| (593) |
Net income attributed to Synopsys | $ 294,781 |
| $ 195,078 |
| $ 608,468 |
| $ 357,423 |
|
|
|
|
|
|
|
|
Net income per share attributed to Synopsys: |
|
|
|
|
|
|
|
Basic | $ 1.93 |
| $ 1.28 |
| $ 3.97 |
| $ 2.34 |
Diluted | $ 1.89 |
| $ 1.24 |
| $ 3.88 |
| $ 2.27 |
|
|
|
|
|
|
|
|
Shares used in computing per share amounts: |
|
|
|
|
|
|
|
Basic | 153,090 |
| 152,725 |
| 153,154 |
| 152,612 |
Diluted | 156,167 |
| 157,077 |
| 156,815 |
| 157,226 |
|
|
|
|
|
|
|
|
(1) Synopsys' second quarter of fiscal year 2022 and 2021 ended on April 30, 2022 and May 1, 2021, respectively. For presentation purposes, we refer to the closest calendar month end. |